Herantis Pharma Announces Paper in Journal Genes on biomarker -driven approaches in Parkinson’s Disease
Herantis Pharma Plc, Press Release, 30 September 2021 at 12:00 EEST Herantis Pharma Plc (“Herantis”), focusing on disease-modifying therapies for debilitating neurodegenerative diseases, today announced that a review describing genetically targeted clinical trials in Parkinson’s disease has been published in Genes, a peer-reviewed open access journal of genetics and genomics. Precision medicine and focus on genetically defined subtypes of disease have been successful in oncology clinical trials in the past decade and similar approaches implementing genetics, biomarkers and smart clinical